Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -4.13% is 49% above its 5-year average of -8.13%, near the high end of its 5-year range (-23.46%–4.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 23.37% below its 12-month average of -3.35%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -4.13%.
RETURN ON EQUITY (ROE)
-4.13%
RETURN ON EQUITY (ROE) AVG TTM
-3.35%
RETURN ON EQUITY (ROE) AVG 3Y
-3.23%
RETURN ON EQUITY (ROE) AVG 5Y
-8.13%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-23.37%
CURRENT VS 3Y AVG
-27.69%
CURRENT VS 5Y AVG
+49.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.75%
median of 681 covered companies
CURRENT VS SECTOR MEDIAN
+89.86%
vs the sector median at left
Castle Biosciences, Inc.
Market Cap
$1.03B
Return on Equity (ROE)
-4.13%
TTM Avg
-3.35%
3Y Avg
-3.23%
5Y Avg
-8.13%
Market Cap
$1.04B
Return on Equity (ROE)
-11.06%
TTM Avg
-9.32%
3Y Avg
-13.81%
5Y Avg
-2.96%
Market Cap
$1.04B
Return on Equity (ROE)
-63.62%
TTM Avg
-41.08%
3Y Avg
-23.78%
5Y Avg
-22.76%
Market Cap
$1.03B
Return on Equity (ROE)
-52.47%
TTM Avg
-18.98%
3Y Avg
-16.96%
5Y Avg
-116.25%
Market Cap
$1.04B
Return on Equity (ROE)
-0.69%
TTM Avg
-24.98%
3Y Avg
-8.92%
5Y Avg
-2.80%
Market Cap
$1.03B
Return on Equity (ROE)
-4.51%
TTM Avg
-33.13%
3Y Avg
-42.62%
5Y Avg
-42.62%
Market Cap
$1.06B
Return on Equity (ROE)
-13.54%
TTM Avg
-40.81%
3Y Avg
-170.75%
5Y Avg
-114.78%
Market Cap
$999.75M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$990.75M
Return on Equity (ROE)
-32.27%
TTM Avg
-24.43%
3Y Avg
-32.70%
5Y Avg
-40.03%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Castle Biosciences, Inc. (CSTL) | $1.03B | -4.13% | -3.35% | -3.23% | -8.13% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.04B | -11.06% | -9.32% | -13.81% | -2.96% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.04B | -63.62% | -41.08% | -23.78% | -22.76% |
| Immatics N.V. (IMTX)vs › | $1.03B | -52.47% | -18.98% | -16.96% | -116.25% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | -0.69% | -24.98% | -8.92% | -2.80% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | -4.51% | -33.13% | -42.62% | -42.62% |
| Teladoc Health, Inc. (TDOC)vs › | $1.06B | -13.54% | -40.81% | -170.75% | -114.78% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $999.75M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $990.75M | -32.27% | -24.43% | -32.70% | -40.03% |
| IRadimed Corporation (IRMD)vs › | $1.08B | 22.66% | 22.95% | 21.85% | 17.09% |
ROE
-4.1%
ROA
-3.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -4.13% |
| 2026-03-31 | -2.78% |
| 2025-12-31 | -5.13% |
| 2025-09-30 | -2.62% |
| 2025-06-30 | -2.08% |
| 2025-03-31 | -1.15% |
| 2024-12-31 | 4.00% |
| 2024-09-30 | 1.38% |
| 2024-06-30 | -0.73% |
| 2024-03-31 | -7.65% |
| 2023-12-31 | -14.69% |
| 2023-09-30 | -19.57% |
| 2023-06-30 | -23.46% |
| 2023-03-31 | -18.62% |
| 2022-12-31 | -16.82% |
| 2022-09-30 | -12.87% |
| 2022-06-30 | -10.55% |
| 2022-03-31 | -13.00% |
| 2021-12-31 | -7.60% |
| 2021-09-30 | -7.23% |
| 2021-06-30 | -5.42% |
| 2021-03-31 | -3.62% |
| 2020-12-31 | -2.47% |
| 2020-09-30 | -2.01% |
| 2020-06-30 | 4.50% |
| 2020-03-31 | 8.19% |
| 2019-12-31 | 6.20% |
| 2019-09-30 | 8.61% |
| 2019-03-31 | -204.61% |
